Abstract
Hypertension is the single largest global contributor to disability-adjusted life years lost. The majority of the aged population have hypertension, and appear to be at increased risk of covid-19 infection. How hypertension modifies the risks and severity of covid-19 and the implications for hypertension treatment is less clear. Therefore, there is currently no reason to discontinue RAS blockers in stable patients facing the COVID-19 pandemic. In COVID-19 patients with severe symptoms, sepsis, or hemodynamic instability RAS blockers and other blood pressure lowering drugs should be used or discontinued on a case-by-case basis, taking into account current guidelines…. Read More